We have found one bond among more than a dozen issued by these two newly merged companies that we consider well very protected from the financial perils that the new company might experience. And because of this, it has an extra high yield, which can lead to extra high profits.
Read More …Download PDF
For only the third time in history, a new energy drink has surpassed the billion-dollar mark in annual sales in the U.S. But this company is not only taking market share from its two main competitors but it’s expanding the size of the overall market.
Read More …Download PDF
Dear Biotech Frontiers subscribers: Shares of Kodiak Sciences (Nasdaq: KOD), part of our original basket of 10-negative-enterprise-value biotech stocks, are up about 100%. We recommended Kodiak at $3.16 per share. Today, shares are trading in the range $6.15 to $6.35. There is no specific news that has driven the re-rating in Kodiak, and the stock
Read More …
In this issue of Biotech Frontiers, we focus on an upstart company that’s playing “pharmaceutical moneyball” – like the gritty Oakland A’s did with discarded baseball players, it looks through a new lens to find drugs that other pharma companies have put on the back shelf.
Read More …Download PDF
While the overall market continues to ride higher, there are signs beneath the surface that suggest things could begin to turn. Taking lessons from a legendary investor, we look at how to avoid getting caught up in the exuberance.
Read More …
Right now the bond market is not sending very many distress signals. But if the mood shifts, we could suddenly have many more bonds trading at yields that make them appealing to investors with the appetite for high risk/high reward.
Read More …
